IP Watchdog

MARCH 21, 2025

This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. by BOE Technology. by BOE Technology. by BOE Technology.

Pharmaceuticals 52

Pharmaceuticals Construction Litigation Technology 52

IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. Today, the U.S. vacating an infringement judgment against Mylan in the Northern District of West Virginia.

Evidence 105

Evidence Pharmaceuticals Construction Litigation 105

IP Watchdog

JULY 13, 2023

Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for Entresto®, which is Novartis’ blockbuster heart medication. In the fall of 2022, Novartis went to trial on the validity of one of the asserted patents, U.S. 8,101,659 (“the ‘659 patent”).

Technology 52

Technology Pharmaceuticals Construction Evidence 52

IP Watchdog

MAY 3, 2022

Venture appealed the district court decision challenging “(I) [the] rejection of its on-sale-bar defense, (II) [the] determination that it infringed two patents we have since held invalid, (III) [the] construction of two claim terms, and (IV) [the] decision to enhance damages.”

Counterclaim 116

Counterclaim Construction Healthcare Pharmaceuticals 116

IP Watchdog

NOVEMBER 8, 2023

Court of Appeals for the Federal Circuit issued yet another decision reinforcing what can only be described as the “lead compound” rule for challenging pharmaceutical and other chemical compound patents on the basis of obviousness. The Federal Circuit has been utilizing the “lead compound” construct since around 2000. Otsuka Pharm.

Construction 52

Construction Pharmaceuticals Litigation 52